Delving into the Latest Updates on Cadi-05 with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine

Synonyms

Immuvac, Leprosy vaccine, Leprovac

+ [8]

Target

TLR2

Action

agonists

Mechanism

TLR2 agonists(Toll like receptor 2 agonists)

Therapeutic Areas

NeoplasmsInfectious DiseasesRespiratory Diseases+ [1]

Active Indication

LeprosyNon-Small Cell Lung Cancer

Inactive Indication

Bladder CancerCOVID-19Head and Neck Neoplasms+ [5]

Originator Organization

National Institute of Immunology

Active Organization

Cadila Pharmaceuticals Ltd.

National Institute of Immunology

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

India (01 Jan 1998),

LeprosyNon-Small Cell Lung Cancer

Regulation-

Login to view timeline

This is a randomized, double blind, two arms, placebo controlled, clinical trial to study to evaluate the the safety and efficacy of Mycobacterium w in combination with standard of care versus placebo with standard of care for preventing the progression of COVID-19 disease and for reduction in transfer to ICU in COVID-19 infected patients admitted to the hospital.

Start Date30 Jun 2020

Sponsor / Collaborator

Cadila Pharmaceuticals Ltd.

[+1]

CTRI/2020/04/024846

/ CompletedPhase 3

A clinical trial to evaluate the safety and efficacy of Mycobacterium W in critically ill patients suffering from COVID 19 infection

Start Date30 Apr 2020

Sponsor / Collaborator

Cadila Pharmaceuticals Ltd.

100 Clinical Results associated with Cadi-05

Login to view more data

100 Translational Medicine associated with Cadi-05

Login to view more data

100 Patents (Medical) associated with Cadi-05

Login to view more data

88

Literatures (Medical) associated with Cadi-05

01 Mar 2025·International Journal of Biological Macromolecules

The bioconjugates of curcumin, zingerone and [6]-shogaol with low molecular weight chitosan: Synthesis, characterization and in vitro anticancer activity in HepG2 cells

Article

Author: Bettadaiah, B K ; Mahesha, Harshitha ; Prashanth, K V Harish

The synthesis of bioconjugates of curcumin, zingerone, and [6]-shogaol with low molecular weight chitosan (LMWC) is presented. The unconjugated forms of these compounds exhibit low water solubility, poor stability, limited bioavailability, and low target specificity, whereas the synthetic conjugates demonstrate improved physical properties. The synthesis was achieved by forming succinates & then reacting with LMWC. They were characterized using FTIR, ¹H NMR, UV-Vis spectroscopy, SEM and DLS analysis. The hydrophilicity of bioconjugates was found to be 10.66 mg/mL for C-LMWC, 17.67 mg/mL for Z-LMWC, and 11.59 mg/mL for S-LMWC. The bioconjugates exhibited enhanced stability compared to the individual compounds. In vitro release studies indicated a rapid release at pH 5.0 and a slower release at pH 7.4, which is favorable for cancer therapeutic applications. Additionally, the anticancer activity of the bioconjugates was evaluated using a cytotoxicity assay on the liver cancer cell line HepG2, displaying IC50 values of 14.01 μg/mL for C-LMWC, 82.53 μg/mL for Z-LMWC, and 9.07 μg/mL for S-LMWC. LMWC is superior to chitosan due to its hydrophilicity & low viscosity. The LMWC conjugates exhibited better solubility, stability and control release of bioactives. The study highlights a better anticancer activity of LMWC-conjugates compared to the native forms.

01 Apr 2024·Scandinavian Journal of Immunology

Activation of neutrophils excels the therapeutic potential of Mycobacterium indicus pranii and heat‐induced promastigotes against antimony‐resistant Leishmania donovani infection

Article

Author: Ray, Monalisa ; Pal, Chiranjib ; Nath, Supriya ; Ghosh, Sanhita ; Dey, Somaditya ; Das, Bedanta ; Roy, Kamalika ; Karan, Mintu ; Mandal, Pritam ; Mukherjee, Soumyadip ; Paul, Sharmistha ; Karmakar, Suman ; Das, Mousumi

AbstractRepurposing drugs and adjuvants is an attractive choice of present therapy that reduces the substantial costs, chances of failure, and systemic toxicity. Mycobacterium indicus pranii was originally developed as a leprosy vaccine but later has been found effective against Leishmania donovani infection. To extend our earlier study, here we reported the immunotherapeutic modulation of the splenic and circulatory neutrophils in favour of hosts as neutrophils actually serve as the pro‐parasitic portable shelter to extend the Leishmania infection specifically during the early entry into the hosts' circulation. We targeted to disrupt this early pro‐parasitic incidence by the therapeutic combination of M. indicus pranii and heat‐induced promastigotes against antimony‐resistant L. donovani infection. The combination therapy induced the functional expansion of CD11b+Ly6CintLy6Ghi neutrophils both in the post‐infected spleen, and also in the circulation of post‐treated animals followed by the immediate Leishmania infection. More importantly, the enhanced expression of MHC‐II, phagocytic uptake of the parasites by the circulatory neutrophils as well as the oxidative burst were induced that limited the chances of the very early establishment of the infection. The enhanced expression of pro‐inflammatory cytokines, like IL‐1α and TNF‐α indicated resistance to the parasite‐mediated takeover of the neutrophils, as these cytokines are critical for the activation of T cell‐mediated immunity and host‐protective responses. Additionally, the induction of essential transcription factors and cytokines for early granulocytic lineage commitment suggests that the strategy not only contributed to the peripheral activation of the neutrophils but also promoted granulopoiesis in the bone marrow.

01 Nov 2023·Indian Dermatology Online Journal

Mycobacterium Indicus Pranii (MIP) Vaccine: Pharmacology, Indication, Dosing Schedules, Administration, and Side Effects in Clinical Practice

Review

Author: Jain, Sejal ; Narang, Tarun ; Chhabra, Seema ; Dogra, Sunil ; Sharma, Ayush

Mycobacterium indicus pranii (MIP), previously called Mw vaccine, is a one-of-a-kind immunomodulatory vaccine. It was indigenously developed in India for use in leprosy. MIP is heat-killed Mycobacterium w, which is a non-pathogenic atypical mycobacterium belonging to Class IV of Runyon classification. It shares epitopes with Mycobacterium leprae and Mycobacterium tuberculosis, which forms the rationale behind its use in leprosy and tuberculosis. MIP activates both innate and acquired immunity. It induces a Th1 and Th17 immune response along with downregulation of Th2 pathway and activates macrophages and dendritic cells. MIP vaccine is safe with adverse effects such as local site erythema, swelling, and rarely fever and other systemic reactions. Apart from leprosy, MIP has been used in dermatological diseases such as warts and psoriasis. Clinical trials have evaluated the efficacy of MIP in a plenitude of non-dermatological conditions such as category II tuberculosis, Gram-negative sepsis, non-small cell lung cancer, human immunodeficiency virus (HIV), muscle-invasive bladder cancer, and very recently, coronavirus 2019 (COVID-19). In vitro and animal studies have also demonstrated its utility in leishmaniasis, melanoma, and as a vaccine for the prevention of pregnancy. The PubMed database was searched using “Mycobacterium indicus pranii, MIP, Mycobacterium w” as the keyword in title. This comprehensive review provides useful information for healthcare professionals about immunotherapeutic potential of MIP vaccine, its composition, dosing schedule, administration, and side effects besides its efficacy in various indications other than leprosy.

100 Deals associated with Cadi-05

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07AX	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Leprosy	India	-	01 Jan 1998
Non-Small Cell Lung Cancer	India	-	01 Jan 1998

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic melanoma	Phase 2	United States	Cadila Pharmaceuticals Ltd.	01 Dec 2006
Prostatic Cancer	Phase 2	India	Cadila Pharmaceuticals Ltd.	-
COVID-19	Preclinical	India	Cadila Pharmaceuticals Ltd.	14 May 2020
Tuberculosis	Preclinical	India	Cadila Pharmaceuticals Ltd.	17 Jul 2018
Sepsis	Preclinical	India	Cadila Pharmaceuticals Ltd.	23 May 2015
Bladder Cancer	Preclinical	India	Cadila Pharmaceuticals Ltd.	-
Head and Neck Neoplasms	Preclinical	India	Cadila Pharmaceuticals Ltd.	-
Multiple Myeloma	Preclinical	India	Cadila Pharmaceuticals Ltd.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Literature Manual	Phase 1	Astrocytoma \| Glioblastoma \| Testicular Neoplasms \| Bronchogenic Carcinoma \| Bladder Cancer \| Fibrosarcoma \| Head and Neck Neoplasms	24	Cadi-05	tfxrdlxirj(vypcffzxzy) = ewcxztywuu wcoupjuees (vwodathwnb )	Positive	20 May 2008